28Dec 2023
Study Shows Tofacitinib-Corticosteroid Combination Enhances Treatment Response in Acute Severe Ulcerative Colitis

Study Shows Tofacitinib-Corticosteroid Combination Enhances Treatment Response in Acute Severe Ulcerative Colitis

A recent double-blind, placebo-controlled trial at a single center focused on patients hospitalized with acute severe ulcerative colitis (ASUC), refractory to intravenous corticosteroids. The study randomized adults to receive tofacitinib or placebo alongside corticosteroids. By day 7, the tofacitinib group showed an 83.01% treatment response compared to 58.82% in the placebo group. Tofacitinib also reduced the need for rescue therapy by day 7 and demonstrated a lower cumulative probability of rescue therapy at day 90. Despite mostly mild adverse effects, one tofacitinib patient experienced dural venous sinus thrombosis. The findings highlight improved treatment outcomes with the tofacitinib-corticosteroid combination for ASUC patients.

  • #gastroenterology

Like

Save

Share